tiprankstipranks
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
The FlyAlto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
16d ago
ANRO
Alto Neuroscience Appoints Andrew Miller to Board
PremiumCompany Announcements
Alto Neuroscience Appoints Andrew Miller to Board
1M ago
8K
ANRO
Alto Neuroscience appoints Miller to Board of Directors
PremiumThe Fly
Alto Neuroscience appoints Miller to Board of Directors
1M ago
ANRO
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
PremiumRatings
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
1M ago
ANRO
Alto Neuroscience price target lowered to $33 from $35 at BofA
PremiumThe Fly
Alto Neuroscience price target lowered to $33 from $35 at BofA
1M ago
ANRO
Alto Neuroscience price target lowered to $36 from $38 at Baird
PremiumThe FlyAlto Neuroscience price target lowered to $36 from $38 at Baird
1M ago
ANRO
Alto Neuroscience price target raised to $24 from $21 at Wedbush
Premium
The Fly
Alto Neuroscience price target raised to $24 from $21 at Wedbush
2M ago
ANRO
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
Premium
Ratings
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
2M ago
ANRO
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
PremiumRatings
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
2M ago
ANRO
Alto Neuroscience Shareholders Shape Governance and Equity Plans
PremiumCompany Announcements
Alto Neuroscience Shareholders Shape Governance and Equity Plans
2M ago
8K
ANRO
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
PremiumThe Fly
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
2M ago
ANRO
Alto Neuroscience initiated with a Buy at BofA
PremiumThe Fly
Alto Neuroscience initiated with a Buy at BofA
2M ago
ANRO
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
PremiumThe FlyAlto Neuroscience presents Phase 2a data for ALTO-207 in MDD
2M ago
ANRO
Alto Neuroscience participates in a conference call with H. C. Wainwright
Premium
The Fly
Alto Neuroscience participates in a conference call with H. C. Wainwright
2M ago
ANRO
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
Premium
The Fly
Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
2M ago
ANRO
Alto Neuroscience files to sell 6M shares of common stock for holders
PremiumThe Fly
Alto Neuroscience files to sell 6M shares of common stock for holders
3M ago
ANRO
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
PremiumThe Fly
Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright
3M ago
ANRO
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
PremiumThe Fly
Alto Neuroscience price target lowered to $21 from $22 at Wedbush
3M ago
ANRO
Morning Movers: Immunovant sinks after batoclimab trials miss goal
PremiumThe Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
3M ago
BP
ALK
Alto Neuroscience price target lowered to $38 from $41 at Baird
PremiumThe FlyAlto Neuroscience price target lowered to $38 from $41 at Baird
3M ago
ANRO
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
Premium
The Fly
Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
3M ago
ANRO
Closing Bell Movers: Globalstar spikes on acquisition report
Premium
The Fly
Closing Bell Movers: Globalstar spikes on acquisition report
3M ago
FC
AMZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >